Related references
Note: Only part of the references are listed.Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
C. L. Boils et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
T. Alhamad et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
L. Spain et al.
ANNALS OF ONCOLOGY (2016)
Belatacept and Long-Term Outcomes in Kidney Transplantation
Flavio Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1
Evan J. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients
Rebecca Pike et al.
FRONTIERS IN IMMUNOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
Harsha A. Ranganath et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Post-transplantation malignancies: here today, gone tomorrow?
Edward K. Geissler
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Rita E. Morales et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systematic review of melanoma incidence and prognosis in solid organ transplant recipients
Erin Dahlke et al.
TRANSPLANTATION RESEARCH (2014)
Role of the PD-1 Pathway in the Immune Response
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Management of targeted therapies in hemodialysis patients
Nicolas Janus et al.
BULLETIN DU CANCER (2012)
Essential Role of PDL1 Expression on Nonhematopoietic Donor Cells in Acquired Tolerance to Vascularized Cardiac Allografts
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Malignant Melanoma in Solid Transplant Recipients: Collection of Database Cases and Comparison With Surveillance, Epidemiology, and End Results Data for Outcome Analysis
Jerry D. Brewer et al.
ARCHIVES OF SURGERY (2011)
Malignant Melanoma in Solid Transplant Recipients Collection of Database Cases and Comparison With Surveillance, Epidemiology, and End Results Data for Outcome Analysis
Jerry D. Brewer et al.
ARCHIVES OF DERMATOLOGY (2011)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Cancer incidence and risk factors after solid organ transplantation
Claire M. Vajdic et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation
Maria-Luisa del Rio et al.
TRANSPLANT INTERNATIONAL (2008)
Medical progress - Skin cancers after organ transplantation
S Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Treatment of a patient with end-stage renal disease with rituximab: Pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis
AP Jillella et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
